New shot aims to tame rare autoimmune disease
NCT ID NCT07641634
First seen Jun 15, 2026 · Last updated Jun 22, 2026 · Updated 1 time
Summary
This early-phase trial tests a new drug called PRO-203, given as a single shot under the skin. First, healthy volunteers will check safety; then, people with systemic sclerosis (a rare autoimmune disease that hardens skin and organs) will receive the drug. The main goal is to see if it's safe and how it affects immune cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLERODERMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Drum Tower Hospital
RECRUITINGNanjing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nucleus Network
COMPLETEDMelbourne, Victoria, 3004, Australia
-
Peking University Third Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRO-203 (a drug given as a shot under the skin)
What this could lead to
If it works, this could point toward a treatment that controls systemic sclerosis by targeting immune cells.
What could go wrong
This is a very early, small trial (44 people) focused on safety, not effectiveness. It may fail to show benefit or have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.